Decreasing Expression of Cancer-Driving Genes with CDK7
SY-5609 is a highly selective and potent oral inhibitor of the cyclin-dependent kinase 7 (CDK7) that is expected to enter a Phase 1 clinical trial in patients with select solid tumors, including breast, lung and ovarian cancers, as well as solid tumors of any histology with a specific molecular signature.
SY-5609 represents a new approach to treating cancer that we believe has potential in a range of difficult-to-treat cancers. It has induced deep and sustained tumor growth inhibition, including complete regressions, as a single agent in preclinical models of breast, ovarian and lung cancers. SY-5609 has also shown substantial anti-tumor activity in combination with fulvestrant in hormone receptor (HR)-positive breast cancer models that are resistant to CDK4/6 inhibitors. SY-5609 has also been shown preclinically to preferentially kill cancer cells over non-cancerous cells.